Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Vivos Therapeutics (VVOS) Accumulated Depreciation & Amortization (2019 - 2025)

Historic Accumulated Depreciation & Amortization for Vivos Therapeutics (VVOS) over the last 7 years, with Q3 2025 value amounting to $3.0 million.

  • Vivos Therapeutics' Accumulated Depreciation & Amortization rose 1118.86% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 1118.86%. This contributed to the annual value of $2.9 million for FY2024, which is 36022.54% up from last year.
  • Latest data reveals that Vivos Therapeutics reported Accumulated Depreciation & Amortization of $3.0 million as of Q3 2025, which was up 1118.86% from $2.7 million recorded in Q2 2025.
  • Vivos Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $3.0 million for Q3 2025, and its period low was $621000.0 during Q4 2023.
  • Over the past 5 years, Vivos Therapeutics' median Accumulated Depreciation & Amortization value was $1.9 million (recorded in 2023), while the average stood at $1.8 million.
  • As far as peak fluctuations go, Vivos Therapeutics' Accumulated Depreciation & Amortization plummeted by 4617.86% in 2022, and later soared by 36022.54% in 2024.
  • Over the past 5 years, Vivos Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $1.2 million in 2021, then plummeted by 46.18% to $669000.0 in 2022, then fell by 7.17% to $621000.0 in 2023, then surged by 360.23% to $2.9 million in 2024, then rose by 6.05% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $2.7 million for Q2 2025, and $2.4 million during Q1 2025.